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INTRODUCTION
The number of early gastric cancer (EGC) diagnoses has
increased in recent decades, due to developments in diagnos-
tic procedures. In Korea, the proportion of EGC patients is
increasing; according to a recent report of the Korea Gastric
Cancer Association, it increased from 28.6% in 1995 to 47.4%
in 2004 (1).
In general, EGC is characterized by a malignant tumor that
is considered ‘‘curable’’, given that the outcome of surgical
treatment is excellent, even in patients with node-positive
disease (2). However, some cases of EGC recur after radical
surgery, in the form of lymphatic spread, blood-borne metas-
tasis, or peritoneal dissemination. Although several studies
have been conducted to identify the clinicopathological fea-
tures of such exceptional cases (3), the predictive histopatho-
logical and immunohistochemical (IHC) parameters for recur-
rence of EGC are not well known.
In the current study, the clinicopathological characteris-
tics and ancillary IHC markers of recurrent EGC were inves-
tigated, in comparison to non-recurrent cancer. 
MATERIALS AND METHODS 
Case selection
A total of 1,788 patients who had undergone curative gas-
trectomy for primary EGC at the Asan Medical Center in
Seoul between 1991 and 2001 were retrospectively analyzed.
All patients had undergone a gastrectomy with sufficient
lymph node dissection, in accordance with the General Rules
for the Gastric Cancer Study of the Japanese Research Soci-
ety for Gastric Cancer (4).
The medical records and database of the Division of Gastric
Surgery, Department of Surgery, Asan Medical Center were
used, as were telephone interviews for gathering follow-up
information. The recurrence of disease was confirmed by radi-
ological studies, endoscopic examination with biopsy, sur-
gery, and the cytological diagnosis of body fluids. Cases with
multiple primary cancers-such as synchronous and metach-
ronous tumors-were excluded. Thirty-four cases with recur-
rence were found, pathologically reexamined and recorded
according to the Guide of the Gastrointestinal Pathology
Study Group of the Korean Society of Pathologists (5). Via
1158
Jeong Won Kim
1,*, Ilseon Hwang
2,� , 
Mi-Jung Kim
2, and Se Jin Jang
2
Department of Pathology
1, Seoul Veterans Hospital,
Seoul; Department of Pathology
2, University of Ulsan
College of Medicine, Asan Medical Center, Seoul,
Korea
Current address: *Department of Pathology, 
Kangnam Sacred Heart Hospital, Hallym University of
College of Medicine, Seoul; 
� Department of Pathology,
Dongsan Medical Center, Keimyung University 
College of Medicine, Daegu, Korea
Address for correspondence
Se Jin Jang, M.D.
Department of Pathology, University of Ulsan College
of Medicine, Asan Medical Center, 388-1 
Pungnap-dong, Songpa-gu, Seoul 138-736, Korea
Tel : +82.2-3010-5966, Fax : +82.2-472-7898
E-mail : jangsejin@amc.seoul.kr
J Korean Med Sci 2009; 24: 1158-64
ISSN 1011-8934
DOI: 10.3346/jkms.2009.24.6.1158
Copyright � The Korean Academy
of Medical Sciences
Clinicopathological Characteristics and Predictive Markers of 
Early Gastric Cancer with Recurrence
Early gastric cancer (EGC) is a ‘‘curable’’ disease with a high cure rate made pos-
sible through proper surgical treatment; nonetheless, some patients sustain a dis-
ease recurrence after curative resection. The aim of this study was to identify the
clinicopathological characteristics of recurrent EGC and determine predictable im-
munohistochemical markers for recurrence. We investigated the clinicopathologi-
cal features of 1,786 EGC cases, and using tissue microarray, the expression of c-
erbB-2, EGFR, MLH1, MSH2, p53, and AQP1 was examined in group with recurrence
and control group without recerrence. In the clinical analysis, 32 of 1,786 (1.79%)
patients showed recurrence, with a 2.04% five-year cumulative recurrence rate. Age,
submucosal invasion, and lymph node metastasis significantly correlated with tumor
recurrence (P=0.044, 0.019, and <0.001, respectively). Multivariate analysis showed
lymph node status and old age (≥57 yr) as independent risk factors of recurrence.
In a case-control study, immunopositivity for c-erbB-2 was significantly associated
with disease recurrence (P=0.024). There is the probability that EGC patients with
old age (≥57 yr), lymph node metastasis, submucosal invasion, and c-erbB-2 im-
munopositivity will experience recurrence; therefore, it is critical that patients with
these risk factors be followed-up closely and considered candidates for adjuvant
treatment.
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pathological reviews, two cases with proper muscle involve-
ment of tumor cells were found and excluded from this study.
The patterns of recurrence were classified into four types:
locoregional recurrence of perigastric lymph nodes and anas-
tomosis site; distant recurrence to the liver, lung, brain, and
distant lymph nodes; peritoneal recurrence, including Kruken-
berg’s tumor and peritoneal carcinomatosis with malignant
ascites; and mixed-type recurrence (6). 
Selection of control group without recurrence
For IHC stains, 32 control cases were selected from 1,754
cases of non-recurrent EGC, via an age and gender-matched
random sampling method. Patient data are summarized in
Table 1.
Tissue microarray design and immunohistochemical
stains 
A tissue microarray (TMA) was constructed from the paraf-
fin-embedded blocks of 64 recurrent and non-recurrent con-
trol cases; for this purpose, a tissue arrayer device (Beecher
Instruments Inc., Sun Prairie, WI, U.S.A.) was used as pre-
viously described (7). Stomach cancers were histologically
reviewed and representative tumor areas were marked in the
corresponding paraffin blocks. Three selected cylinders (1.5
mm in the largest dimension) from three different tumor areas
were included for each case. TMA blocks were each sectioned
at a thickness of 4 μ m; the sections were mounted on pre-
coated glass slides and deparaffinized. IHC assays were per-
formed using a Ventana NX automated immunohistochem-
istry system (Ventana Medical Systems, Tucson, AZ, U.S.A.)
with monoclonal/polyclonal primary antibodies to c-erbB-2
(A0485, rabbit polyclonal, Dako, Glostrup, Denmark; dilu-
tion 1:500), EGFR (NOVO-L-EGFR, rabbit monoclonal,
Novocastra, Newcastle upon Tyne, U.K.; dilution 1:50),
MLH1 (13291A, mouse monoclonal, PharMingen, San Di-
ego, CA, U.S.A.; dilution 1:50), MSH2 (65051A, mouse mon-
oclonal, PharMingen; dilution 1:500), p53 (M7001, mouse
monoclonal, Dako; dilution 1:3,000), and AQP1 (AQP11-
4, rabbit polyclonal, Alpha Diagnostic International Inc.,
San Antonio, TX, U.S.A.; dilution 1:50). 
Immunohistochemical evaluation 
According to the scoring system recently proposed by Hof-
mann et al. (8), the results of IHC staining for c-erbB-2 were
scored as follows: 0, no reactivity or membranous reactivity
in <10% of tumor cells; 1+, faintly/barely perceptible mem-
branous reactivity in ≥10% of tumor cells; 2+, weak to
moderate membranous complete or basolateral membranous
reactivity in ≥10% of tumor cells; 3+, moderate to strong
complete or basolateral membranous stain in ≥10% of tumor
cells (Fig. 1). Only a membranous stain-either complete or
incomplete-was considered meaningful, not a cytoplasmic
stain. The score of IHC stain for c-erbB-2 was classified as
negative (score 0 and 1+), equivocal (score 2+), and posi-
tive (score 3+). 
For EGFR, reactivity was scored as 0 when there was no
membranous reactivity within the tumor; the positive sam-
ples were classified further into 1+, 2+, and 3+, based on
intensity of reactivity. The highest intensity of reactivity of
all tissue cores from the same tumor was used as the final IHC
Parameters
Un-recurred
cases (%)
Control
cases (%)
Recurred
cases (%)
P
value
Age (yr, mean±SD) 54.7±11.7 59.3±11.8 58.9±12.3 0.044
≤40 246 (14.0) 3 (9.4) 4 (12.5)
>40 1,508 (86.0) 29 (90.6) 28 (87.5)
Sex (male:female) 1,152:602 21:11 21:11 NS
Type of surgery NS
TG 183 (10.4) 2 (6.3) 2 (6.3)
SG 1,549 (88.3) 30 (93.7) 30 (93.7)
PG 22 (1.3) 0 0
Tumor location NS
Upper  87 (5.0) 1 (3.1) 1 (3.1)
Middle 547  (31.2) 11  (34.4) 8  (25)
Lower  1,120 (63.8) 20 (62.5) 23 (71.9)
Tumor size  2.98±1.89 2.80±1.42 3.14±1.79 NS
Tumor free margin  3.28±1.65 3.77±1.91 2.98±1.08 NS
Gross type NS
Protruded 75 (4.3) 1 (3.1) 2 (6.2)
Superficial elevated 101 (5.8) 4 (12.5) 2 (6.2)
Flat 168 (9.6) 1 (3.1) 1 (3.1)
Superficial depressed 691 (39.4) 13 (40.6) 10 (31.3)
Excavated 105 (5.9) 3 (9.4) 5 (41.7)
Mixed 614 (35.0) 10 (21.3) 12 (37.5)
Histologic type NS
Tubular 1,438 (81.9) 27 (84.4) 28 (87.5)
Signet ring cell 296 (16.9) 5 (15.6) 4 (12.5)
Mucinous 15 (0.9) 0 0 (0.0)
Other 5 (0.3) 0 1 (3.1)
Differentiation NS
WD 420 (23.9) 4 (12.5) 7 (21.9)
MD 506 (28.8) 13 (40.6) 11 (34.4)
PD 828 (47.2) 15 (46.9) 14 (43.8)
Depth of invasion 0.019
Mucosa 876 (49.9) 15 (46.9) 9 (28.1)
Submucosa 878 (50.1) 17 (53.1) 23 (71.9)
Lymph node metastasis
0 1,570 (89.5) 26 (81.3) 12 (37.5) <0.001
1-5 166 (9.5) 5 (15.6) 12 (37.5) OR=9.5
6-15 16 (0.9) 1 (3.1) 7 (21.9) 57.2
>15 2 (0.1) 0 1 (3.1) 65.4
Table 1. Clinicopathological parameters in relation to the study
of recurrent early gastric cancer 
SD, standard deviation; TG, total gastrectomy; SG, subtotal gastrecto-
my; PG, proximal gastrectomy; WD, well differentiated; MD, moderate-
ly differentiated; PD, poorly differentiated; NS, not significant; OR, odds
ratio.1160 J.W. Kim, I. Hwang, M.-J. Kim, et al.
result for that tumor. Scores of 2+ and 3+ were considered
suggestive of overexpression (9). A positive stain for MLH1/
MSH2 was defined as an unequivocal nuclear stain in the
neoplastic cells, and for AQP1, as membranous and/or cyto-
plasmic stain. Cases with nuclear staining in >10% of tumor
cells were defined as p53-positive reactions.
Statistical analysis
Univariate analyses-including a t-test, a Pearson’s chi-square
test, and a logistic regression test-were used to compare data
between the groups with and without recurrent cancer. In
addition, a multivariate analysis was performed using the Cox
proportional hazards model. The five-year cumulative recur-
rence rate of survival data was measured using the Kaplan-
Meier method. All calculations were performed using the
Statistical Package for the Social Sciences (SPSS) software
program, version 14.0 (SPSS Inc., Chicago, IL, U.S.A.), and
results were considered statistically significant when the P
value was <0.05.
RESULTS 
Recurrence rate and mortality 
Of the 1,786 patients surgically treated for EGC, 32 pa-
tients (1.79%) had sustained a disease recurrence and 1,754
were disease-free. The five-year cumulative recurrence rate
was 2.04%. Thirty-one of the 32 recurrent patients (93.9%)
died. The sole surviving patient had undergone a primary
operation in 1998 and a secondary resection in 2001 for lym-
phoepithelial carcinoma. The mean interval between opera-
tion and recurrence was 20 months, while the mean survival
period after recurrence was 9.6 months.
Recurrence pattern
Of the 32 recurrent cases, nine (28.1%) had a locoregion-
al recurrence, one (3.1%) had a peritoneal dissemination, 12
(37.5%) had distant metastasis and 10 (31.3%) had a mixed-
type recurrence. The nine cases of locoregional recurrence
included four cases with perigastric lymph node involvement
and five with carcinoma in an anastomotic site, with no simul-
Fig. 1. c-erbB2 immunohistochemical analysis. (A) 1+, faint (×100); (B) 2+, weak to moderate complete membranous (×200); (C) 3+,
strong and complete membranous (×400); and (D) 3+, strong basalateral membranous reactivities (×400).
A
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taneous cancer and sufficient tumor-free margins at the time
of primary operation. Tumor recurrence in an anastomotic
site occurred at a mean interval of 19 months. At initial diag-
nosis, one case had a mucosal tumor with perigastric lymph
node metastasis and four had submucosal tumors with no
lymph node metastasis. Four patients underwent reoperation,
and 28 cases were managed with chemotherapy and conser-
vative treatment.
Clinicopathological parameters predicting recurrence
The mean age of the patients with disease recurrence was
58.9±12.3 yr at the time of operation-somewhat older than
the non-recurrent group (54.7±11.7). Age correlated with
the incidence of recurrence (P=0.044) (Table 1). 
In the cases with recurrence, lymph node metastasis was
positive in 20 cases (58.8%) and, in the group without recur-
rence, positive in 184 cases (10.5%). Recurrence was signif-
icantly frequent in cases with lymph node metastasis (P<
0.001). Among the node-positive patients with recurrence,
there were 12 patients with <6 positive node (N1), seven
with 7-15 (N2), and one with >16 (N3). Logistic regression
analysis indicated that the N-stage at the time of surgery was
a strong predictor of recurrence (P<0.001; odds ratio [OR]=
8 [N1], 49 [N2]56 [N3]). In the recurrent group, there were
23 cases with submucosal invasion (71.9%), whereas there
were 878 cases in the non-recurrent group (50.1%; P=0.019).
According to multivariate analysis, old age (≥57 yr) and
lymph node metastasis were independent risk factors of recur-
rence (Table 2).
Other clinicopathological features-including gender, tumor
size, tumor location, histological type, gross type, differen-
tiation, and distance from safety margin-did not correlate
with recurrence.
Immunohistochemical markers predicting recurrence
Positive staining for c-erbB-2 (score 3+) was found in six
(18.8%) recurrent cases, but not in any non-recurrent con-
trol cases (P=0.024; Table 3). Three cases showed moderate-
ly to strongly basolateral membranous staining, and the other
three cases sustained complete membranous staining. One
case with tumor heterogeneity displayed 3+ tumor cells rep-
resenting ≥10% of the tumor area. All c-erbB-2-positive
cases were of the tubular and intestinal type, and one case
showed poor differentiation. Regarding tumors with equiv-
ocal positivity (score 2+), there were two cases in the recur-
rent group and one in the non-recurrent control group. The
mean survival period of immunopositive cases for c-erbB-2
was 21 months and that of the remaining c-erbB-2-negative
and equivocally positive recurrent cases was 32.6 months.
Only two (6.3%) recurrent cases showed membranous im-
munoreactivity for EGFR; they were of a tubular type and
moderately differentiated. However, no non-recurrent case
showed immunopositivity for EGFR (P=0.492). The mean
survival period for EGRF-positive cases was 38.6 months.
Nuclear immunoreactivity for MSH2 was found in 19 (59.4
%) recurrent cases and 12 (37.5%) control cases (P=0.133).
Regarding the expression of MLH1, AQP1, and p53, there
was no statistically significant association between the recur-
rent and non-recurrent control cases (P=0.430, 0.317, and
0.799, respectively).
DISCUSSION
The recurrence of EGC is very rare in general, and the recur-
rence rate of EGC treated by curative surgery reportedly varies,
from 1.4 to 6.4% (10-12). Recently, however, a study by Wu
et al. (13) showed that post-gastrectomy recurrence was ob-
served in 12.24% of the cases studied. This variation is due
to what is considered recurrent carcinoma arising in the rem-
nant gastric stump; some researchers take up the position
that carcinoma in the residual stomach should be excluded
from any recurrence analysis, because it is difficult to distin-
guish second primary carcinomas in the gastric stump from
RR, relative risk; CI, confidence interval.
Factors RR 95% CI P value
LN metastasis 13.95 6.38-30.51 0.00
Age (≥57 yr) 2.48 1.19-5.17 0.01
Depth 1.06 0.46-2.47 0.88
Table 2. Multivariate analysis of clinicopathological factors asso-
ciated with early gastric cancer recurrence
Markers Recurred group Control group P value
C-erbB-2 0.024
Positive 6 0
Equivocal 2 1
Negative 24 31
EGFR 0.492
Positive 2 0
Negative 30 32
MLH1 0.430
Positive 10 14
Negative 22 22
MSH2 0.133
Positive 19 12
Negative 13 20
P53 0.799
Positive 14 12
Negative 18 20
AQP1 0.317
Positive 18 13
Negative 14 19
Table 3. Expression of immunohistochemical markers in group
with recurrence and control group without recurrence1162 J.W. Kim, I. Hwang, M.-J. Kim, et al.
synchronous tumors that had been initially overlooked (12)
or a metachronous tumor. In the current study, we included
five cases found in the anastomotic site, by definition of mul-
tiple primary cancers (14). In none of the five cases were there
any simultaneous cancers, and all five had a sufficient tumor-
free margin at the time of primary operation. Furthermore,
the initial tumor and secondary tumor showed the same mor-
phological features.
With regards to EGC recurrence patterns, most researchers
have reported that a distance recurrence via a hematogenous
spread was the most common recurrence pattern. Folli et al.
(15) reported that 14 out of 22 patients with recurrent EGC
showed hematogenous recurrence, while Lee et al. (6) report-
ed that distant recurrence was the most common pattern of
recurrence (42.9%). The current study showed a similar result,
with distance recurrence occurring in 37.5% of the cases,
making it the most common recurrence pattern. In submu-
cosal EGC, hematogenous recurrence could be explained by
the mechanism of lymphatic and vascular invasions during
the submucosal invasion of cancer cells (16). However, a sat-
isfactory explanation for hematogenous recurrence has not
yet been suggested vis-a$-vis mucosal cancer.
The risk factors related to EGC recurrence have been dis-
cussed in several articles (6). Ichiyoshi et al. (10) reported that
the elevated type, positive lymph node, and invasion of lym-
phatic and venous vessels were significantly associated with
a high risk of recurrence. Shiozawa et al. (11) considered some
other factors, such as submucosal invasion, a gross appearance
of IIa+IIc type, and a tumor size >40 mm. Using multivari-
ate analysis, Lee et al. (6) proposed that lymph node metas-
tasis was the only significant prognostic factor, and that N-
stage correlates with the five-year survival rate. Other stud-
ies (17, 18) repeatedly have proposed that lymph node metas-
tasis is one of the most important diagnostic factors of EGC.
As a rule, there is at least a thread of connection between lym-
phatic involvement at the time of operation and hematoge-
nous and distant metastasis. A report of Wu et al. (13) stat-
ed that lymph node metastasis was an independent risk fac-
tor for short-term recurrence; however, in their series, 86%
(26/30) of the recurrent patients had no lymph node metas-
tasis at the time of operation, even though hematogenous
and lymphatic metastasis was the most common recurrence
pattern (33%). They proposed micrometastasis, as a means
of reconciling these findings. Therefore, we assert that a patho-
logically careful examination of lymph node status is neces-
sary with a surgically resected stomach. In any case, the cita-
tion of submucosal invasion and age as prognostic factors in
EGC recurrence remains controversial (6, 12, 13, 19). 
With respect to advanced gastric carcinoma, many studies
have been performed to find predictive factor for recurrence.
However, ancillary IHC markers have not been investigated
in cases of EGC with recurrence, in comparison to non-recur-
rent cancer. 
For IHC staining, we randomly selected from among the
non-recurrent cases an age and gender-matched control group.
The clinicopathological features of the control group repre-
sented most of the characteristics of the non-recurrent cases;
however, despite the use of the random selection method, the
proportion of cases with lymph node metastasis in the con-
trol group (18.7%) was higher than in the non-recurrent
group (10.5%), and there were differences between the two
groups in terms of such objects as tumor size and distance
from safety margin (Table 1). 
We chose to examine some IHC markers related to poor
prognosis of gastric cancer. The EGF receptor/ligand system
seems to be involved in the regulation of gastric mucosal pro-
liferation and the progression of gastric carcinomas. In uni-
variate and multivariate analyses, EGFR levels were found
to be an independent indicator of poor prognosis (20, 21).
Previous reports (22, 23) suggested that a high overexpres-
sion rate of the growth factor receptor oncogene c-erbB-2 was
significantly related with metastasis and an advanced stage
of stomach cancer, as well as poor tumor differentiation. We
found the overexpression of c-erbB-2 could be considered a
predictor of poor outcome in EGC as well as in advanced gas-
tric cancer; however, we also found that the rates of c-erbB-
2 immunoreactivity in tumors with well, moderate, and poor
differentiation were 33% (2/6), 50% (3/6), and 17% (1/6),
respectively. A high correlation between cerbB2 expression
and intestinal type has been reported in many previous stud-
ies and confirmed in more recent studies (24, 25).
Unlike in breast carcinoma, the concordance between pro-
tein expression and gene amplification of c-erbB-2 in gastric
cancer has been considered controversial (24, 25). In addition,
the evaluation of c-erbB-2 immunohistochemisty with respect
to gastric cancer tend to be more ambiguous than with breast
cancer, due to tumor heterogeneity and higher frequency of
glandular formations in the former. Therefore, the importance
of an objective and specialized c-erbB-2 scoring system for
gastric cancer becomes increasingly obvious. We used the
proposed and modified HercepTestTM score for gastric cancer,
as discussed in an international consensus meeting by Hof-
mann et al. (8) According to the validation study, identical
scoring should be applied to samples with complete mem-
branous reactivity, as well as those where reactivity was res-
tricted to the basolateral membrane if such reactivity was
noted in ≥10% of cells. Samples with cohesive 3+ tumor
cells were considered positive, irrespective of size (8).
Gastric cancers have one of the highest prevalences of mic-
rosatellite instability (MSI) with up to 33% of cases (26). Wu
et al. (27) demonstrated that a subset of sporadic gastric can-
cer with high-frequency MSI (MSI-H) showed a clinicopatho-
logical profile (i.e., higher frequency of antral location, intesti-
nal subtype, and H. pylori seropositivity, but lower incidence
of lymph-node metastasis) distinct from those with low-fre-
quency MSI (MSI-L) or microsatellite stability (MSS). To more
fully understand the implications of the more frequent im-
munoreactivities vis-a$-vis MSH2 in our results, additionalRecurrence of Early Gastric Cancer 1163
MSI-related studies are required.
The tumor suppressor gene p53 encodes for a nuclear pro-
tein that plays a key role in tumor progression by regulating
DNA repair, cell division, and apoptosis. p53 expression was
found to be higher in poorly differentiated gastric carcino-
mas than in well-differentiated ones (28). According to Pan
et al. (29), tumors in the metastatic EGC group had higher
p53 expression than those from the non-metastatic group. 
Aquaporins (AQP) are integral membrane proteins having
more than 10 isoforms in mammalian cells that serve as chan-
nels in the transfer of water and, in some cases, small solutes
across the membrane. AQP1 found in the blood vessels, kid-
ney proximal tubules, eye, and ear was considered to play a
role in tumor angioinvasion and progression (30). However,
in the current study, there were no differences between the
recurrent and non-recurrent cases, with respect to staining
patterns and intensities of AQP1.
In conclusion, the recurrence of EGC is very rare in gener-
al. However, it is well known that the management of recur-
rent tumors is difficult, owing to the presence of extra-gas-
trointestinal lesions and combined types of recurrence. The
presence of lymph node metastasis, old age, submucosal inva-
sion, and c-erbB-2 immunopositivities imply higher possi-
bility of recurrence; therefore, post-gastrectomy patients pos-
sessing these traits should be closely followed and considered
candidates for adjuvant treatment.
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